JCOG0509_2B: JCOG0509, figure 2B

JCOG0509_2BR Documentation

JCOG0509, figure 2B

Description

Kaplan-Meier digitized data from JCOG0509, figure 2B (PMID 24638015). A reported sample size of 284 for a primary endpoint of OS in lung cancer.

Usage

JCOG0509_2B

Format

A data frame of 284 observations and 3 variables:

time event time (in months)
event PFS event indicator (0: no event, 1: event)
arm treatment arms (amrubicin_cisplatin, irinotecan_cisplatin)

Source

Satouchi M, Kotani Y, Shibata T, et al. Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509. J Clin Oncol 2014; 32: 1262–8.

Examples

summary(JCOG0509_2B)

kmplot(JCOG0509_2B)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.